<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMZ)</span><br/>(tri-meth'o-prim-sul-fa-meth'ox-a-zole)<br/><span class="topboxtradename">Bactrim, </span><span class="topboxtradename">Co-Trimoxazole, </span><span class="topboxtradename">Septra<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">urinary tract agent</span>; <span class="classification">sulfonamide</span><br/><b>Prototype: </b>Trimethoprim<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>80 mg trimethoprim/400 mg sulfamethoxazole, 160 mg trimethoprim/800 mg sulfamethoxazole tablets; 40 mg trimethoprim/200 mg sulfamethoxazole/5 ml suspension; 16 mg trimethoprim/80 mg sulfamethoxazole/5 ml, 80 mg trimethoprim/400 mg sulfamethoxazole/5 ml injection</p>
<h1><a name="action">Actions</a></h1>
<p>Fixed combination of sulfamethoxazole (SMZ), an intermediate acting antiinfective sulfonamide, and trimethoprim (TMP), a synthetic
         antiinfective. Both components of the combination are synthetic folate antagonist antiinfectives. Mechanism of action is principally
         enzyme inhibition, which prevents bacterial synthesis of essential nucleic acids and proteins.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against <i>Pneumocystis carinii</i> pneumonitis, <i>Shigellosis enteritis,</i> and severe complicated UTIs due to most strains of the <i>Enterobacteriaceae</i>. Bacterial resistance to the combined drugs develops more slowly than to either of the drugs alone.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>
<i>Pneumocystis carinii</i> pneumonitis, <i>Shigellosis</i> enteritis, and severe complicated UTIs due to most strains of the <i>Enterobacteriaceae</i>. Also children with acute otitis media due to susceptible strains of <i>Haemophilus influenzae,</i> and acute episodes of chronic bronchitis in adults.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Isosporiasis; prevention of traveler's diarrhea; cholera; treatment of infections caused by <i>Nocardia, Legionella micdadei,</i> and <i>Legionella pneumophila</i> and genital ulcers caused by <i>Haemophilus ducreyi;</i> prophylaxis for <i>P. carinii</i> pneumonia in neutropenic patients.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to TMP, SMZ, sulfonamides, or bisulfites; group A beta-hemolytic streptococcal pharyngitis; megaloblastic
         anemia due to folate deficiency; creatinine clearance 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney or liver function; possible folate deficiency; severe allergy or bronchial asthma; G6PD deficiency, hypersensitivity
         to sulfonamide derivative drugs (e.g., acetazolamide, thiazides, tolbutamide).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Systemic Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 160 mg TMP/800 mg SMZ [1 double strength (DS) tablet] q12h <span class="rdroute">IV</span> 810 mg/kg/d TMP divided q612h infused over 6090 min<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;2 mo &amp;  4 mg/kg/d TMP q12h; <i>&gt;40 kg,</i> 160 mg TMP/800 mg SMZ (1 DS tablet) q12h <span class="rdroute">IV</span>
<i>&gt;2 mo,</i> 810 mg/kg/d TMP divided q612h infused over 6090 min<br/><br/><span class="indicationtitle">
<i>Pneumocystis carinii</i> Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 20 mg/kg/d TMP divided q6h infused over 6090 min<br/><br/><span class="indicationtitle">Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 160 mg TMP/800 mg SMZ q24h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 150 mg/m<sup>2</sup> TMP/750 mg/m<sup>2</sup> SMZ b.i.d. 3 consecutive d/wk (max: 320 mg TMP/d)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 1030 mL/min: reduce dose by 50%; <br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with a full glass of desired fluid.</li>
<li>Maintain adequate fluid intake (at least 1500 mL/d) during therapy.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Add contents of 5-mL ampul to 125 mL D5W. Use within 6 h. If less fluid is desired, dilute in 75 or 100 mL and use within
                  2 h or 4 h, respectively. Do not refrigerate.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span>  Give over 6090 min. Avoid bolus or rapid injection. Do not mix other drugs or solutions with IV infusion. Discard solution
                  if cloudy or if crystallization appears after mixing.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> Stability in <b>dextrose</b> and <b>normal saline</b> is concentration dependent; <b>fluconazole,</b>
<b>verapamil.</b>
<span class="incompattype">Y-site:</span>
<b>Fluconazole,</b>
<b>foscarnet,</b>
<b>midazolam,</b>
<b>vinorelbine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) in dry place protected from light. Avoid freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span>
<span class="speceff-common">Mild to moderate rashes (including fixed drug eruptions),</span>
<span class="speceff-life">toxic epidermal necrolysis</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> diarrhea, <span class="speceff-common">anorexia,</span> hepatitis, <span class="speceff-life">pseudomembranous enterocolitis</span>, stomatitis, glossitis, abdominal pain. <span class="typehead">Urogenital:</span> Kidney failure, oliguria, anuria, crystalluria. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Agranulocytosis</span> (rare), <span class="speceff-life">aplastic anemia</span> (rare), megaloblastic anemia, hypoprothrombinemia, thrombocytopenia (rare). <span class="typehead">Body as a Whole:</span> Weakness, arthralgia, myalgia, photosensitivity, <span class="speceff-life">allergic myocarditis</span>. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May elevate levels of serum creatinine, transaminase, bilirubin, alkaline phosphatase.</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May enhance hypoprothrombinemic effects of <span class="classification">oral anticoagulants</span>; may increase <b>methotrexate</b> toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 14 h PO.  <span class="typehead">Distribution:</span> Widely distributed, including CNS; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 810 h TMP, 1013 h SMZ. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be aware that IV Septra contains sodium metabisulfite, which produces allergic-type reactions in susceptible patients: Hives,
            itching, wheezing, anaphylaxis. Susceptibility (low in general population) is seen most frequently in asthmatics or atopic
            nonasthmatic persons.
         </li>
<li>Lab tests: Baseline and followup urinalysis; CBC with differential, platelet count, BUN and creatinine clearance with prolonged
            therapy.
         </li>
<li>Monitor coagulation tests and prothrombin times in patient also receiving warfarin. Change in warfarin dosage may be indicated.</li>
<li>Monitor I&amp;O volume and pattern. Report significant changes to forestall renal calculi formation. Also report failure of treatment
            (i.e., continued UTI symptoms).
         </li>
<li>Older adult patients are at risk for severe adverse reactions, especially if liver or kidney function is compromised or if
            certain other drugs are given. Most frequently observed: Thrombocytopenia (with concurrent thiazide diuretics); severe decrease
            in platelets (with or without purpura); bone marrow suppression; severe skin reactions.
         </li>
<li>Be alert for overdose symptoms (no extensive experience has been reported): Nausea, vomiting, anorexia, headache, dizziness,
            mental depression, confusion, and bone marrow depression.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately to physician if rash appears. Other reportable symptoms are sore throat, fever, purpura, jaundice; all
            are early signs of serious reactions.
         </li>
<li>Monitor for and report fixed eruptions to physician. This drug can cause fixed eruptions at the same sites each time the drug
            is administered. Every contact with drug may not result in eruptions; therefore, patient may overlook the relationship.
         </li>
<li>Drink 2.53 liters (1 liter is approximately equal to 1 quart) daily, unless otherwise directed.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>